CCK (Cholecystokinin) & Receptors Drug Discovery Landscape & Assay Solutions
- By admin
- 08 Oct 2026
- Comments
Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCK and CCK Receptor drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCK / CCK1R / CCK2R Recombinant Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CCK Products |
| Gene Delivery | CCK1R / CCK2R Promise-ORF / Lentivirus Full-length GPCR ORF for stable cell line construction and functional assays. |
View CCK1R Products |
| Benchmark Ab | Anti-CCK / Anti-CCK2R Recombinant Antibodies Recombinant positive control for binding and internalization assays. |
View CCK2R Products |
| Validator | CCK1R / CCK2R siRNA Set For knockdown verification and specificity controls. |
View CCK Products |
| Related Target A | GLP1R (Glucagon-Like Peptide 1 Receptor) Synergistic metabolic pathway partner; co-agonist target for obesity. |
View GLP1R Products |
| Related Target B | Gastrin (Gastrin/CCK2R Ligand) Endogenous homolog ligand; critical for selectivity and cross-reactivity profiling. |
View Gastrin Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving GPCR Conformation for Screening | Lentivirus for Stable Cell Line generation ensures native 7-transmembrane folding. |
| CCK1R vs. CCK2R Subfamily Selectivity | Sequence Verified recombinant receptor fragments and cell lines for counter-screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for target-specific knockdown verification |
Live CCK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the Cholecystokinin (CCK) system has diverged into two highly lucrative clinical domains: metabolic regulation (primarily via CCK1R) and oncology (primarily via CCK2R). In metabolic disease, CCK1R co-agonism is being integrated into multi-receptor peptide therapeutics (GLP-1R/GIPR/CCK1R) to maximize satiety and weight loss. In oncology, CCK2R represents an elite target for Radioligand Therapy (RLT) and imaging in medullary thyroid cancer and gastrointestinal tumors.
The race for CCK-related therapeutics is intensifying, with major players shifting focus from traditional small-molecule antagonists to peptide-drug conjugates, radioligands, and multi-specific biologics. As first-generation radioligands reach late-stage clinical trials, the next wave of R&D is targeting receptor internalization kinetics and sub-nanomolar selectivity to avoid off-target gastrointestinal toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Radioligand Therapy (RLT) | Debiopharm, ITM, Novartis | Medullary Thyroid Cancer, GI Tumors | Internalization Assay (Need high-expression CCK2R stable cell lines) |
| Multi-agonist Peptides | Eli Lilly, Novo Nordisk | Obesity, Type 2 Diabetes | Functional GPCR Activation (Need CCK1R Lentivirus for Calcium/cAMP assays) |
| Monoclonal Antibodies / ADCs | Academic Institutes, Biotech | Solid Tumors | Selectivity Assay (Need CCK1R vs CCK2R recombinant protein panels) |